

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6393535

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DIFFERENTIAL DRUG DEVELOPMENT ASSOCIATES LLC	09/08/2017
RECEIVING PARTY DATA	
Name:	MARIUS PHARMACEUTICALS LLC
Street Address:	8601 SIX FORKS ROAD
Internal Address:	SUITE 630
City:	RALEIGH
State/Country:	NORTH CAROLINA
Postal Code:	27615
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16834277
CORRESPONDENCE DATA	
Fax Number:	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 428-0200
Email:	patentadmin@clarkelbing.com
Correspondent Name:	CLARK & ELBING LLP
Address Line 1:	101 FEDERAL STREET
Address Line 2:	15TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	51241-004004
NAME OF SUBMITTER:	JEFFREY J. ELLISON, PH.D.
SIGNATURE:	/Jeffrey J. Ellison, Ph.D./
DATE SIGNED:	11/10/2020
Total Attachments: 2	
source=51241-004002 - DDDA to Marius Assignment as Filed#page1.tif	
source=51241-004002 - DDDA to Marius Assignment as Filed#page2.tif	

Attorney Docket No. 51241/001001

CONFIRMATORY ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	State of Incorporation	Business Address
Differential Drug Development Associates LLC	North Carolina	101 Guymon Court Morrisville NC 27560

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Marius Pharmaceuticals LLC	Delaware	8601 Six Forks Road Suite 630 Raleigh NC 27615

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent, or their foreign counterparts, identified as:

Title of Application	Filing Date	Serial Number
MODULATION OF SOLUBILITY, STABILITY, ABSORPTION, METABOLISM, AND PHARMACOKINETIC PROFILE OF LIPOPHILIC DRUGS BY STEROLS	December 31, 2009	U.S. Prov. Serial No. 61/291,769
	December 31, 2010	PCT/US2010/062649
	December 31, 2010	U.S. Serial No. 12/983,216
	July 5, 2013	U.S. Serial No. 13/936,036
	December 31, 2010	Europe Appl. No. EP10841783.3
	December 31, 2010	Europe Appl. No. EP10841783.3
	December 31, 2010	Canada Appl. No. CA20102822435
	December 31, 2010	Hong Kong Appl. No. HK14106868
	December 31, 2010	India Appl. No. 1959/KOLNP/2012
	December 31, 2010	Japan Appl. No. JP2012-0547323
	June 13, 2013	Japan Appl. No. JP2013-0124891
EMULSION FORMULATIONS	March 15, 2013	U.S. Serial No. 13/843,223
	July 3, 2013	PCT/US2013/049405
	July 3, 2013	Europe Appl. No. EP13877592.9
	July 3, 2013	China Appl. No. CN201380074669
	July 3, 2013	Hong Kong Appl. No. HK20160107216
	July 3, 2013	New Zealand Appl. No. NZ20130631833
	March 14, 2014	Taiwan Appl. No. TW20140109505

This assignment includes said applications, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

opdhingra

Om Dhingra
President & CEO
Differential Drug Development Associates LLC

Sept. 8, 2017
Date

Witness:

Sudha Dhingra
Signature

Sept. 8, 2017
Date

Sudha Dhingra Printed name

[Signature]

Himanshu H. Shah
Chairman
Marius Pharmaceuticals LLC

September 8, 2017
Date

Witness:

[Signature]
Signature

September 8, 2017
Date

CHAYA RAD Printed name